Clinical Trials

12 enrolled 12 charts

CNSSarcoma

Neuroblastoma, Osteosarcoma

NCT04854499 2025-11-19

ELEVATE HNSCC

193 enrolled 27 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04958785 2025-11-04

ELEVATE TNBC

92 enrolled 27 charts

Breast

Triple Negative Breast Neoplasms

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

4 enrolled 11 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04541017 2025-10-16

Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment

Phase 1/2 Terminated

8 enrolled 8 charts

Mycosis Fungoides, Sezary Syndrome

NCT05169944 2025-07-09

PNOC025

13 enrolled

CNS

Brain Neoplasms

NCT05330429 2025-07-01

ELEVATE CRC

77 enrolled 22 charts

Colorectal Neoplasms

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT04827576 2025-05-08

ELEVATELung&UC

106 enrolled 22 charts

Other solid neoplasm

Solid Tumor

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

36 enrolled 17 charts

Plasma cell

Multiple Myeloma

NCT04435691 2025-04-27

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Phase 1/2 Terminated

110 enrolled

Leukemia, Myeloid, Acute

NCT05079230 2025-04-04

ENHANCE-3

Phase 3 Terminated

378 enrolled 29 charts

Phase 2 Active not recruiting

Leukemia, Myeloid, Acute

NCT04788043 2025-04-02

Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma

8 enrolled

Hodgkin Disease

NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

54 enrolled 26 charts

Myeloid Malignancies

NCT04778397 2025-02-05

ENHANCE-2

Phase 3 Terminated

258 enrolled 25 charts

Leukemia, Myeloid, Acute

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

11 enrolled 16 charts

Phase 1 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06532344 2024-11-14

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

32 enrolled

MyeloidOther hematologic neoplasm

Pancreatic Neoplasms

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Phase 1 Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06540261 2024-09-19

The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer

Phase 1 Active not recruiting

65 enrolled

MyeloidOther hematologic neoplasm

Unresectable Colorectal Cancer

NCT05807126 2024-05-02

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Phase 1 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Phase 1/2 Withdrawn

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT03558139 2024-04-01

Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy

34 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT05627466 2024-02-15

US Expanded Access Program for Magrolimab in Patients With Relapsed or Refractory Acute Myeloid Leukemia

No longer available

Classical hematologyOther hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05829434 2024-02-12

MAGROLIC

Phase 2 Withdrawn

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT05929716 2023-11-13

An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Withdrawn

Lymphoma, B-Cell

NCT03527147 2022-08-15

PRISM

30 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03922477 2022-02-21

A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

Phase 1 Terminated

13 enrolled 12 charts

Leukemia, Myeloid, Acute

NCT02953782 2021-03-01

Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer

Phase 1/2 Completed

78 enrolled 27 charts

Colorectal Neoplasms

NCT02678338 2019-02-21

CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies

MyeloidOther hematologic neoplasm

20 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02216409 2019-02-05

Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody